Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
fragile X syndrome
Biotech
Stalicla pledges $270M for Novartis' failed fragile X asset
Novartis kept the faith in mavoglurant after it failed a genetic disorder trial. Now, Stalicla has put up $270 million to take the asset forward.
James Waldron
Jan 9, 2023 8:06am
Merck KGaA taps into Quris' stem cell-powered drug screening AI
Feb 14, 2022 10:15am
Ovid pens deal to offload twice-failed former lead program
Feb 8, 2022 9:10am
Quris launches with $9M for AI to predict drug success, safety
Oct 18, 2021 7:30am
Ovid's fragile X drug shows promise in phase 2
May 7, 2020 10:35am
Shionogi boosts Tetra Alzheimer's deal, nabs buyout option
Mar 6, 2020 9:07am
